PROTARA THERAPEUTICS RECEIVES BOTH FDA BREAKTHROUGH THERAPY AND FAST TRACK DESIGNATIONS FOR TARA-002 IN PEDIATRIC PATIENTS WITH LYMPHATIC MALFORMATIONS

Reuters · 01/05 13:00

Please log in to view news